Cullinan Therapeutics Inc

CGEM is in a Stage 3 distribution phase with a medium-term bearish bias; price has broken key support and EMAs have rolled into resistance, and short-term momentum favors further downside. We recommend Sell Now on any rallies into the 9/21 EMA and 50 DMA resistance zone, expecting rejection at these levels in alignment with a speculative strategy’s high-selectivity discipline.

• ↑Strong Buy consensus with $30 median price target implies 65.5% upside
• ↑289 funds hold 66.2M shares; bullish 0.37 put/call ratio
• ↓Negative profitability and earnings yield highlight lack of positive cash flow